{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T19:46:35Z","timestamp":1740167195755,"version":"3.37.3"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T00:00:00Z","timestamp":1700438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T00:00:00Z","timestamp":1700438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s40120-023-00559-5","type":"journal-article","created":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T13:02:34Z","timestamp":1700485354000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Podcast on Identifying and Understanding Barriers to Care in Underserved Populations With MS in the United States"],"prefix":"10.1007","volume":"13","author":[{"given":"Sandra","family":"Parawira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Reese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,20]]},"reference":[{"key":"559_CR1","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1177\/1352458520970841","volume":"26","author":"C Walton","year":"2020","unstructured":"Walton C, King R, Rechtman L, et al. Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition. Mult Scler. 2020;26:1816\u201321.","journal-title":"Mult Scler"},{"key":"559_CR2","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1212\/01.WNL.0000145762.60562.5D","volume":"63","author":"BAC Cree","year":"2004","unstructured":"Cree BAC, Khan O, Bourdette D, et al. Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis. Neurology. 2004;63:2039\u201345.","journal-title":"Neurology"},{"key":"559_CR3","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s12883-020-01749-6","volume":"20","author":"RJ Romanelli","year":"2020","unstructured":"Romanelli RJ, Huang Q, Lacy J, Hashemi L, Wong A, Smith A. Multiple sclerosis in a multi-ethnic population from Northern California: a retrospective analysis, 2010\u20132016. BMC Neurol. 2020;20:163.","journal-title":"BMC Neurol"},{"key":"559_CR4","doi-asserted-by":"publisher","first-page":"e1818","DOI":"10.1212\/WNL.0000000000200151","volume":"98","author":"AM Langer-Gould","year":"2022","unstructured":"Langer-Gould AM, Gonzales EG, Smith JB, Li BH, Nelson LM. Racial and ethnic disparities in multiple sclerosis prevalence. Neurology. 2022;98:e1818\u201327.","journal-title":"Neurology"},{"key":"559_CR5","unstructured":"Brayo P, Kimbrough D. Multiple sclerosis in the Black population of the United States. Practical Neurology [Internet]. 2021. Available from https:\/\/practicalneurology.com\/articles\/2021-feb\/multiple-sclerosis-in-the-black-population-of-the-united-states. Accessed April 5, 2023."},{"key":"559_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103248","volume":"56","author":"CA P\u00e9rez","year":"2021","unstructured":"P\u00e9rez CA, Lincoln JA. Racial and ethnic disparities in treatment response and tolerability in multiple sclerosis: a comparative study. Mult Scler Relat Disord. 2021;56: 103248.","journal-title":"Mult Scler Relat Disord"},{"key":"559_CR7","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1177\/1352458516679894","volume":"23","author":"RE Ventura","year":"2017","unstructured":"Ventura RE, Antezana AO, Bacon T, Kister I. Hispanic Americans and African Americans with multiple sclerosis have more severe disease course than Caucasian Americans. Mult Scler. 2017;23:1554\u20137.","journal-title":"Mult Scler"},{"key":"559_CR8","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1212\/WNL.0b013e3181e8e72a","volume":"75","author":"I Kister","year":"2010","unstructured":"Kister I, Chamot E, Bacon JH, et al. Rapid disease course in African Americans with multiple sclerosis. Neurology. 2010;75:217\u201323.","journal-title":"Neurology"},{"key":"559_CR9","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1159\/000484213","volume":"50","author":"L Amezcua","year":"2018","unstructured":"Amezcua L, Rivas E, Joseph S, Zhang J, Liu L. Multiple sclerosis mortality by race\/ethnicity, age, sex, and time period in the United States, 1999\u20132015. Neuroepidemiology. 2018;50:35\u201340.","journal-title":"Neuroepidemiology"},{"key":"559_CR10","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1177\/1352458506070923","volume":"12","author":"RT Naismith","year":"2006","unstructured":"Naismith RT, Trinkaus K, Cross AH. Phenotype and prognosis in African-Americans with multiple sclerosis: a retrospective chart review. Mult Scler. 2006;12:775\u201381.","journal-title":"Mult Scler"},{"key":"559_CR11","doi-asserted-by":"publisher","first-page":"3115","DOI":"10.1093\/brain\/awy245","volume":"141","author":"N Gonzalez Caldito","year":"2018","unstructured":"Gonzalez Caldito N, Saidha S, Sotirchos ES, et al. Brain and retinal atrophy in African-Americans versus Caucasian-Americans with multiple sclerosis: a longitudinal study. Brain. 2018;141:3115\u201329.","journal-title":"Brain"},{"key":"559_CR12","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1007\/s00415-013-7054-4","volume":"260","author":"L Amezcua","year":"2013","unstructured":"Amezcua L, Lerner A, Ledezma K, et al. Spinal cord lesions and disability in Hispanics with multiple sclerosis. J Neurol. 2013;260:2770\u20136.","journal-title":"J Neurol"},{"key":"559_CR13","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1002\/acn3.646","volume":"5","author":"L Amezcua","year":"2018","unstructured":"Amezcua L, Beecham AH, Delgado SR, et al. Native ancestry is associated with optic neuritis and age of onset in Hispanics with multiple sclerosis. Ann Clin Transl Neurol. 2018;5:1362\u201371.","journal-title":"Ann Clin Transl Neurol"},{"key":"559_CR14","first-page":"205521731772510","volume":"3","author":"L Amezcua","year":"2017","unstructured":"Amezcua L, Oksenberg JR, McCauley JL. MS in self-identified Hispanic\/Latino individuals living in the US. Mult Scler J Exp Transl Clin. 2017;3:2055217317725103.","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"559_CR15","unstructured":"Fitzgerald KC, Pimental Maldonado D, Mowry EM. Comorbidity disparities in multiple sclerosis. Practical Neurology [Internet]. 2021. Available from https:\/\/practicalneurology.com\/articles\/2021-feb\/comorbidity-disparities-in-multiple-sclerosis. Accessed April 5, 2023."},{"key":"559_CR16","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1001\/archneurol.2008.541","volume":"66","author":"BAC Cree","year":"2009","unstructured":"Cree BAC, Reich DE, Khan O, et al. Modification of multiple sclerosis phenotypes by African ancestry at HLA. Arch Neurol. 2009;66:226\u201333.","journal-title":"Arch Neurol"},{"key":"559_CR17","first-page":"221","volume":"22","author":"S Klineova","year":"2012","unstructured":"Klineova S, Nicholas J, Walker A. Response to disease modifying therapies in African Americans with multiple sclerosis. Ethn Dis. 2012;22:221\u20135.","journal-title":"Ethn Dis"},{"key":"559_CR18","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1001\/archneur.62.11.1681","volume":"62","author":"BAC Cree","year":"2005","unstructured":"Cree BAC, Al-Sabbagh A, Bennett R, Goodin D. Response to interferon beta-1a treatment in African American multiple sclerosis patients. Arch Neurol. 2005;62:1681\u20133.","journal-title":"Arch Neurol"},{"key":"559_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103830","volume":"63","author":"L Saidenberg","year":"2022","unstructured":"Saidenberg L, Arbini AA, Silverman GJ, Lotan I, Cutter G, Kister I. Faster B-cell repletion after anti-CD20 infusion in Black patients compared to white patients with neurologic diseases. Mult Scler Relat Disord. 2022;63: 103830.","journal-title":"Mult Scler Relat Disord"},{"key":"559_CR20","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1212\/WNL.94.15_supplement.1950","volume":"94","author":"L Tardo","year":"2020","unstructured":"Tardo L, Greenberg B, Horton L. Utilization of health resources and disease modifying therapy use in a high risk, underserved multiple sclerosis patient population and associated impact on disease progression and disability. Neurology. 2020;94:1950.","journal-title":"Neurology"},{"key":"559_CR21","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1191\/1352458505ms1215oa","volume":"11","author":"D Shabas","year":"2005","unstructured":"Shabas D, Heffner M. Multiple sclerosis management for low-income minorities. Mult Scler. 2005;11:635\u201340.","journal-title":"Mult Scler"},{"key":"559_CR22","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2147\/RMHP.S70173","volume":"8","author":"K Hacker","year":"2015","unstructured":"Hacker K, Anies M, Folb BL, Zallman L. Barriers to health care for undocumented immigrants: a literature review. Risk Manag Healthc Policy. 2015;8:175\u201383.","journal-title":"Risk Manag Healthc Policy"},{"key":"559_CR23","unstructured":"The Society for Women's Health Research, United States Food and Drug Administration Office of Women's Health. Dialogues on diversifying clinical trials. https:\/\/www.fda.gov\/downloads\/ScienceResearch\/SpecialTopics\/WomensHealthResearch\/UCM334959.pdf. Accessed April 5, 2023."},{"key":"559_CR24","doi-asserted-by":"publisher","first-page":"e880","DOI":"10.1212\/WNL.0000000000013230","volume":"98","author":"HM Onuorah","year":"2022","unstructured":"Onuorah HM, Charron O, Meltzer E, et al. Enrollment of non-White participants and reporting of race and ethnicity in phase III trials of multiple sclerosis DMTs: a systematic review. Neurology. 2022;98:e880\u201392.","journal-title":"Neurology"},{"key":"559_CR25","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1212\/WNL.0000000000013224","volume":"98","author":"RH Hamilton","year":"2022","unstructured":"Hamilton RH, Ciccarelli O. Non-White participants matter in white matter disease studies: the importance of diversity in multiple sclerosis clinical trials. Neurology. 2022;98:345\u20136.","journal-title":"Neurology"},{"key":"559_CR26","doi-asserted-by":"publisher","first-page":"170","DOI":"10.7224\/1537-2073.2019-131","volume":"23","author":"DA Pimentel Maldonado","year":"2021","unstructured":"Pimentel Maldonado DA, Moreno A, Williams MJ, et al. Perceptions and preferences regarding multiple sclerosis research among racial and ethnic groups. Int J MS Care. 2021;23:170\u20137.","journal-title":"Int J MS Care"},{"key":"559_CR27","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1002\/cpt.2819","volume":"113","author":"A Corneli","year":"2023","unstructured":"Corneli A, Hanlen-Rosado E, McKenna K, et al. Enhancing diversity and inclusion in clinical trials. Clin Pharmacol Ther. 2023;113:489\u201399.","journal-title":"Clin Pharmacol Ther"},{"key":"559_CR28","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1007\/s13187-014-0696-9","volume":"30","author":"S Daverio-Zanetti","year":"2015","unstructured":"Daverio-Zanetti S, Schultz K, del Campo MA, Malcarne V, Riley N, Sadler GR. Is religiosity related to attitudes toward clinical trials participation? J Cancer Educ. 2015;30:220\u20134.","journal-title":"J Cancer Educ"},{"key":"559_CR29","unstructured":"Accelerated Cure Project. Multiple Sclerosis Minority Health Hub. Research and reports on minority participation in clinical trials and MS in minority communities. https:\/\/www.acceleratedcure.org\/ms-minority-health-hub. Accessed April 5, 2023."},{"key":"559_CR30","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1212\/WNL.0000000000200791","volume":"98","author":"AF Okai","year":"2022","unstructured":"Okai AF, Howard AM, Williams MJ, et al. Advancing care and outcomes for African American patients with multiple sclerosis. Neurology. 2022;98:1015\u201320.","journal-title":"Neurology"},{"key":"559_CR31","first-page":"205521732199594","volume":"7","author":"H Chiong-Rivero","year":"2021","unstructured":"Chiong-Rivero H, Robers M, Martinez A, et al. Effectiveness of film as a health communication tool to improve perceptions and attitudes in multiple sclerosis. Mult Scler J Exp Transl Clin. 2021;7:2055217321995947.","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"559_CR32","unstructured":"Multi-Regional Clinical Trials. Diversity, inclusion, and equity in clinical research. https:\/\/mrctcenter.org\/diversity-in-clinical-research\/about\/about-this-work-timeline\/. Accessed April 5, 2023."},{"key":"559_CR33","unstructured":"Hahn SM. FDA offers guidance to enhance diversity in clinical trials, encourage inclusivity in medical product development. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-offers-guidance-enhance-diversity-clinical-trials-encourage-inclusivity-medical-product. Accessed May 15, 2023."},{"key":"559_CR34","unstructured":"Multiple Sclerosis: You Are Not Alone. Welcome to MS. Y.A.N.A. https:\/\/www.msyana.org\/. Accessed April 5, 2023."},{"key":"559_CR35","unstructured":"National Multiple Sclerosis Society. Black MS experience program series. https:\/\/www.nationalmssociety.org\/Resources-Support\/Library-Education-Programs\/Black-MS-Experience. Accessed April 5, 2023."},{"key":"559_CR36","unstructured":"National Multiple Sclerosis Society. Hispanic\/Latinx MS experience summit. https:\/\/www.nationalmssociety.org\/Resources-Support\/Library-Education-Programs\/Hispanic-Latinx-MS-Experience-Summit. Accessed April 5, 2023."},{"key":"559_CR37","unstructured":"Multiple Sclerosis Association of America. The MS and Hispanic American experience. https:\/\/mymsaa.org\/PDFs\/hispanic_american_FAQ_english.pdf. Accessed April 5, 2023."},{"key":"559_CR38","unstructured":"We Are ILL. Who we are. https:\/\/www.weareillmatic.com\/about-us. Accessed April 5, 2023."}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-023-00559-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-023-00559-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-023-00559-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T14:11:40Z","timestamp":1705155100000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-023-00559-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,20]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["559"],"URL":"https:\/\/doi.org\/10.1007\/s40120-023-00559-5","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"type":"print","value":"2193-8253"},{"type":"electronic","value":"2193-6536"}],"subject":[],"published":{"date-parts":[[2023,11,20]]},"assertion":[{"value":"25 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Sandra Parawira: None. Victoria Reese: None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}